Under the terms Pharma Nostra will offer Embria’s EpiCor and eXselen branded ingredients to the entire Brazilian market.
"Pharma Nostra's broad customer base throughout Brazil's $1.7 billion OTC market will further strengthen EpiCor and eXselen's international presence and effectively increase our market share," said Paul Faganel, Embria’s president.
Embria's current distribution base includes Canada’s Alliance Nutritional Ingredients and the US’ B&D Nutritional Ingredients.





